Ad Blocker Detected
Our website is made possible by displaying online advertisements to our visitors. Please consider supporting us by disabling your ad blocker.
SOUTH SAN FRANCISCO, Calif., May 24, 2021 (GLOBE NEWSWIRE) – Fluidigm Corporation (NASDAQ: FLDM), an innovator in biotechnology tools with a vision to improve lives through deep health insights, today announced that she has joined the FLAMIN-. GO project consortium of academic and industry-leading rheumatology, autoimmune disease, and drug discovery and development companies to create an organ-on-a-chip solution for personalized care and improved outcomes in rheumatoid arthritis (RA) patients.
Organ-on-a-Chip refers to a microfluidic culture device that simulates the microarchitecture and functions of living human organs and potentially offers an alternative to traditional animal testing.
RA, an autoimmune inflammatory disease characterized by inflammation of the synovial joint, affects ~ 0.5 to 1 percent of the world’s population. RA is a significant public health problem as it can lead to permanent disability. To gain insight into this disease, scientists from the FLAMIN-GO project are working on developing a next-generation personalized synovia-on-chip (SoC) that mimics the biological complexity in the rheumatic joint. To assist consortium researchers, Fluidigm provides training, support and equipment to conduct Imaging Mass Cytometry ™ (Imaging Mass Cytometry ™) studies using a Hyperion ™ imaging system at the University of Eastern Piedmont in Novara, Italy.
IMC studies will provide critical data on patterns of protein expression between different cell types within the SoC, as well as how the spatial relationship between different cell types affects their activity and response to treatment.
“Approximately 40 percent of RA patients do not achieve even a 20 percent improvement in disease activity with currently approved therapies, and many patients respond to non-approved treatments,” said Dr. Annalisa Chiocchetti, Associate Professor of Immunology at the University of Eastern Piedmont and FLAMIN-GO project coordinator. “The lack of biomarkers that can predict or monitor response to therapy is a significant barrier to determining which approved therapy offers the best safety and efficacy profile for a given patient, as well as reducing clinical development time and the cost of examination therapies.
“We believe that IMC studies with Fluidigm’s Hyperion Imaging System will provide deeper insights into disease mechanisms, biomarkers and factors that influence response to therapy, moving us closer to our goal of enabling personalized medical approaches and bettering patients with RA Deliver results. “
The aim is to use the SoC for patient-specific clinical studies to identify and validate biomarkers that can adapt any RA patient to the approved therapy that is most likely to offer optimal safety, efficacy and tolerability. The SoC would also enable the rapid discovery and evaluation of novel therapeutic targets and open the door for the development of additional therapies based on a deeper understanding of RA biology and response to therapy.
“International consortia such as the FLAMIN-GO project, which focus on a diverse range of expertise and skills to find solutions to global human health problems, are vital for science to take to the next level in precision medicine,” said Chris Linthwaite, President and CEO of Fluidigm. “We are pleased that the FLAMIN-GO project has selected our Hyperion Imaging System as the main tool in its efforts to find a new approach to clinical trials in rheumatoid arthritis.”
In addition to Fluidigm and the University of Eastern Piedmont, the partners of the FLAMIN-GO project consortium include the Instituto Nacional de Engenharia Biomédica, the Institute for Nanotechnology of the Italian National Research Council, the Queen Mary University of London, the Association for Research that Cures (ARCA) . Riga Technical University and EnginSoft Turkey.
About Fluidigm
Fluidigm (Nasdaq: FLDM) focuses on the most pressing needs in translational and clinical research, including cancer, immunology and immunotherapy. Using proprietary CyTOF® and microfluidic technologies, we develop, manufacture and market multi-omic solutions to gain meaningful insights into health and disease, identify biomarkers to make decisions and accelerate the development of more effective therapies. Our customers are the world’s leading academic, government, pharmaceutical, biotechnological, plant and animal research and clinical laboratories. Together with them, we strive to improve the quality of life for everyone. Visit fluidigm.com for more information.
Fluidigm, the Fluidigm logo, Advanta, CyTOF, Hyperion, Imaging Mass Cytometry, and IMC are trademarks and / or registered trademarks of Fluidigm Corporation in the United States and / or other countries. The Advanta ™ Dx SARS-CoV-2 RT-PCR Assay is intended for in vitro diagnostic use. It is only intended for use under emergency approval. Rx only. Other Fluidigm products are intended for research use only. Not for use in diagnostic procedures.
Forward-looking statements for Fluidigm
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding the anticipated customer and application benefits of Fluidigm products. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from those currently anticipated, including, but not limited to, risks associated with challenges in the development, manufacture, introduction, marketing and sale of new products . potential problems with product performance and quality; Intellectual property risks; Competition; Reduce research and development expenses or change budget priorities by customers. Information about these and additional risks and uncertainties and other information that affects Fluidigm’s business and operating results can be found in Fluidigm’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020, as well as in the others with Securities and Exchange Commission. These forward-looking statements speak only as of the date of this agreement. Fluidigm disclaims any obligation to update these forward-looking statements unless required by law.
Available information
We use our website (fluidigm.com), investor page (investors.fluidigm.com), Twitter company account (@fluidigm), Facebook page (facebook.com/Fluidigm) and LinkedIn page (linkedin.com/company/fluidigm- Companies) as sales channels for information about our products, our planned financial and other announcements, our participation in upcoming investor and industry conferences, and other matters. This information can be considered material information and we can use these channels to meet our disclosure obligations under Regulation FD. Therefore, investors should monitor our website and social media accounts in addition to our press releases, SEC filings, public conference calls, and webcasts.
About FLAMIN-GO
FLAMIN-GO’s mission is to develop a next-generation personalized Synovia-on-Chip that enables patient-specific clinical studies on the chip by effectively mimicking the complexity of a rheumatoid arthritic joint. This includes i) selecting the best drug on the market for treating each patient in order to achieve the greatest possible benefit, reducing the risk of side effects, and ii) enabling the rapid discovery and testing of new therapeutic targets to enable a new drug development pathway to determine.
Fluidigm
Media:
Mark Spearman
Senior Director, Corporate Communications
650 243 6621
mark.spearman@fluidigm.com
Investors:
Peter DeNardo
415 389 6400
ir@fluidigm.com
